

Jennifer Landsberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1451147/publications.pdf>

Version: 2024-02-01

75
papers

4,015
citations

172457

29
h-index

128289

60
g-index

80
all docs

80
docs citations

80
times ranked

9504
citing authors

#	ARTICLE	IF	CITATIONS
1	Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. <i>Nature</i> , 2014, 507, 109-113.	27.8	547
2	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. <i>Nature</i> , 2012, 490, 412-416.	27.8	506
3	5â€²-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. <i>Nature Medicine</i> , 2008, 14, 1256-1263.	30.7	353
4	Immune Cellâ€œPoor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. <i>Cancer Discovery</i> , 2014, 4, 674-687.	9.4	226
5	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	14.3	207
6	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. <i>Nature Communications</i> , 2015, 6, 8755.	12.8	175
7	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.9	126
8	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. <i>Clinical Chemistry</i> , 2017, 63, 1288-1296.	3.2	97
9	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. <i>Oncogene</i> , 2018, 37, 6136-6151.	5.9	91
10	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.9	80
11	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	14.3	79
12	<i>LAG3</i> (<i>LAG-3</i> , <i>CD223</i>) DNA methylation correlates with <i>LAG3</i> expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
13	CTLA4 methylation predicts response to antiâ€œPD-1 and antiâ€œCTLA-4 immunotherapy in melanoma patients. <i>JCI Insight</i> , 2018, 3, .	5.0	67
14	Genomeâ€œwide association study identifies new susceptibility loci for cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2015, 24, 510-515.	2.9	66
15	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1462-1464.	1.2	65
16	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations. <i>EBioMedicine</i> , 2018, 28, 97-104.	6.1	55
17	<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. <i>Oncotarget</i> , 2018, 9, 641-650.	1.8	50
18	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. <i>Clinical Epigenetics</i> , 2019, 11, 161.	4.1	49

#	ARTICLE	IF	CITATIONS
19	Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy. <i>Cancer Research</i> , 2009, 69, 6265-6274.	0.9	46
20	Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. <i>European Journal of Cancer</i> , 2016, 59, 109-112.	2.8	45
21	Promoter methylation of the immune checkpoint receptor <i>PD-1</i> (<i>PDCD1</i>) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncology</i> , 2016, 5, e1221555.	4.6	43
22	H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade. <i>Clinical Epigenetics</i> , 2020, 12, 24.	4.1	43
23	Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 133-140.	3.3	40
24	Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. <i>European Journal of Immunology</i> , 2011, 41, 3028-3039.	2.9	40
25	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. <i>EBioMedicine</i> , 2020, 52, 102647.	6.1	38
26	<i>PDCD1</i> (<i>PD-1</i>) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 41011-41020.	1.8	38
27	The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma. <i>Journal of Experimental Medicine</i> , 2017, 214, 339-358.	8.5	37
28	Autochthonous primary and metastatic melanomas in <i>Hgf</i> ^{R24C} mice evade T cell-mediated immune surveillance. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 649-660.	3.3	34
29	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. <i>Cancer Research</i> , 2016, 76, 251-263.	0.9	33
30	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. <i>BMC Cancer</i> , 2020, 20, 355.	2.6	33
31	Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in <i>Hgf</i> ^{R24C} C57BL/6 mice. <i>International Journal of Cancer</i> , 2011, 129, 285-294.	5.1	32
32	The landscape of <i>CD28</i> , <i>CD80</i> , <i>CD86</i> , <i>CTLA4</i> , and <i>ICOS</i> DNA methylation in head and neck squamous cell carcinomas. <i>Epigenetics</i> , 2020, 15, 1195-1212.	2.7	32
33	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. <i>EBioMedicine</i> , 2020, 59, 102962.	6.1	31
34	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. <i>Immunity</i> , 2020, 53, 564-580.e9.	14.3	27
35	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. <i>Clinical Epigenetics</i> , 2020, 12, 94.	4.1	26
36	A key role of GARP in the immune suppressive tumor microenvironment. <i>Oncotarget</i> , 2016, 7, 42996-43009.	1.8	26

#	ARTICLE	IF	CITATIONS
37	The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 372-377.	0.7	25
38	Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸ F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	5.0	25
39	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. <i>Oncolmmunology</i> , 2012, 1, 287-357.	4.6	24
40	DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature. <i>EBioMedicine</i> , 2019, 48, 341-352.	6.1	22
41	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	4.2	22
42	Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. <i>Radiology</i> , 2021, 301, 602-609.	7.3	22
43	Comorbidity Burden and Presence of Multiple Intracranial Lesions Are Associated with Adverse Events after Surgical Treatment of Patients with Brain Metastases. <i>Cancers</i> , 2020, 12, 3209.	3.7	21
44	Stromal Fibroblast-Specific Expression of ADAM-9 Modulates Proliferation and Apoptosis in Melanoma Cells In Vitro and In Vivo. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2451-2458.	0.7	20
45	Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage III-IV M1c melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 759-769.	4.2	20
46	Detailed analysis of adenosine A2a receptor (<i>ADORA2A</i>) and CD73 (5'-nucleotidase, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38) in melanoma. <i>Oncolmmunology</i> , 2018, 7, e1452579.	4.6	19
47	Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis. <i>Cancers</i> , 2021, 13, 3353.	3.7	18
48	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. <i>Clinical Chemistry</i> , 2019, 65, 559-568.	3.2	17
49	Efficacy of Ablative Laser Treatment in Galli-Galli Disease. <i>Archives of Dermatology</i> , 2011, 147, 317.	1.4	15
50	Clinical Management of Locally Advanced Basal-Cell Carcinomas and Future Therapeutic Directions. <i>Dermatology and Therapy</i> , 2020, 10, 835-846.	3.0	14
51	Outcome of Elderly Patients With Surgically Treated Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 713965.	2.8	14
52	Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. <i>Oncolmmunology</i> , 2016, 5, e1078964.	4.6	13
53	Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Diagnostics</i> , 2021, 11, 2314.	2.6	13
54	Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases. <i>Journal of Clinical Medicine</i> , 2021, 10, 634.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Tumor rejection in <i>Cblb</i> ^{hi} mice depends on IL-9 and Th9 cells. , 2021, 9, e002889.		11
56	Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 699860.	2.8	11
57	The Impact of Prolonged Mechanical Ventilation on Overall Survival in Patients With Surgically Treated Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 658949.	2.8	10
58	Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 319-324.	2.4	9
59	DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. <i>Clinical Epigenetics</i> , 2022, 14, 50.	4.1	9
60	Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1785-1787.	3.0	6
61	Joint reconstruction and classification of tumor cells and cell interactions in melanoma tissue sections with synthesized training data. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2019, 14, 587-599.	2.8	6
62	Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 611.	2.8	6
63	DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon- β Signature, Signatures of Immune Infiltrates, and Survival. <i>Journal of Immunotherapy</i> , 2022, 45, 194-206.	2.4	6
64	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. <i>BMC Cancer</i> , 2019, 19, 1024.	2.6	5
65	Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options. <i>Anticancer Research</i> , 2021, 41, 999-1004.	1.1	5
66	It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac036.	0.2	4
67	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. <i>BMC Cancer</i> , 2021, 21, 526.	2.6	3
68	Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in <i>Trex1</i> deficiency. <i>iScience</i> , 2021, 24, 102833.	4.1	3
69	Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13525-e13525.	1.6	3
70	¹⁸ F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor. <i>Oncology Letters</i> , 2016, 12, 4705-4707.	1.8	2
71	Grzybowski's Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Disease—An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report. <i>Dermatology and Therapy</i> , 2021, 11, 625-638.	3.0	2
72	Phymatous Transformation of Facial Cutaneous Vascular Malformations: Clues to Phyma Pathogenesis. <i>JAMA Dermatology</i> , 2013, 149, 368.	4.1	1

#	ARTICLE	IF	CITATIONS
73	32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii5-ii6.	0.7	1
74	The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival. <i>Journal of Clinical Medicine</i> , 2021, 10, 4013.	2.4	1
75	Treatment of metastasized melanoma with combined checkpoint inhibition in a patient with highly active multiple sclerosis. <i>Journal of Dermatology</i> , 2020, 47, e184-e185.	1.2	0